Lifeward Ltd. (LFWD) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Lifeward Ltd. is a medical device company focused on physical rehabilitation (ReWalk exoskeletons, AlterG anti-gravity systems) and has recently expanded into biomedical technologies. The quarter was defined by a strategic transaction with Oramed Pharmaceuticals Inc., involving the acquisition of Oratech Pharmaceuticals Ltd. and significant related-party financing. The company operates as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $3.92 million | $5.03 million |
| Gross Profit | $1.34 million | $2.12 million |
| Gross Margin | 34.2% | 42.2% |
| Net Loss | $(10.79) million | $(4.83) million |
| Net Loss Per Share (Basic/Diluted) | $(6.70) | $(5.53) |
| Operating Cash Flow | $(3.68) million | $(5.49) million |
| Cash and Cash Equivalents (End of Period) | $11.42 million | $5.73 million |
| Total Debt (Convertible Notes) | $7.28 million (Long-term) | $2.80 million (Current) |
Note: Share counts reflect a 1-for-12 reverse stock split effective February 24, 2026.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 22% year-over-year, primarily due to a $1.3 million drop in AlterG revenue caused by supply chain timing issues and working capital constraints. This was partially offset by growth in ReWalk revenue.
- Significant R&D Increase: Research and development expenses surged to $5.85 million (from $0.92 million) due to a one-time $4.95 million charge for acquired in-process research and development (IPR&D) related to the Oratech acquisition.
- Financing Activity: The company executed a major strategic transaction with Oramed, issuing $10 million in new convertible notes ("New Notes") and equity instruments. This replaced prior bridge notes and significantly increased long-term liabilities.
- Liquidity Improvement: Despite operating losses, cash balances increased from $2.17 million to $11.42 million, driven by $6.5 million in cash acquired from Oratech and $6.42 million in net financing proceeds.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for at least 12 months from the date of issuance, despite recent financing. Additional capital will be required to fund operations.
- Strategic Expansion: The acquisition of Oratech adds a biomedical pipeline, specifically the ORMD-0801 oral insulin candidate, for which Phase 2 trial preparations are advancing. The company also completed an agreement to acquire upper-body robotic orthotic technology from Skelable Ltd.
- Reimbursement Progress: Management highlighted progress in Medicare reimbursement for the ReWalk Personal Exoskeleton, including a favorable Administrative Law Judge ruling and established fee schedules.
- Risks: Key risks include reliance on third-party manufacturers (Cirtronics for AlterG), the need for continued capital raises, integration risks with Oratech, and potential delisting from Nasdaq if listing requirements are not met.
Investor Verification Checklist
- Going Concern Status: Verify the company's specific plan and timeline for raising additional capital to address the substantial doubt disclosure.
- Oratech Integration: Assess the timeline and milestones for the ORMD-0801 Phase 2 trial and the revenue-sharing agreement with Oramed.
- Debt Covenants: Review the terms of the $10 million "New Notes" (8% interest, maturity March 2029) and the associated warrant liabilities to understand dilution and repayment obligations.
- Supply Chain: Confirm the resolution of working capital constraints that previously impacted AlterG shipments and revenue.
- Reverse Split Impact: Monitor the impact of the 1-for-12 reverse split on share liquidity and compliance with Nasdaq Capital Market listing standards.